Surrozen

SRZNNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$189.937 M

$16.16 -8.18%

Close of 23 Sept 2026

Revenue

$3.48M

#3342 by revenue

Earnings

-$242.0M

Loss-making

Shares outstanding

11,753,558

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#97Innate PharmaIPHA$196.6M
#98Coherus OncologyCHRS$194.7M
#99SurrozenSRZN$189.9M
#100Voyager TherapeuticsVYGR$176.8M
#101Precision BiosciencesDTIL$175.5M

What if Surrozen were worth as much as…

Open the what-if tool →

Gold $29.8T

$2,539,395

Per share 157,141× higher

Bitcoin $1.69T

$144,136.81

Per share 8,919× higher

Nvidia $5.43T

$462,395.39

Per share 28,614× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Surrozen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 24 Sept 2026. Read the methodology.